Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QuilliChew ER in pediatric ADHD
NCT01654250Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2012
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Pfizer. Started Jul 2012; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01654250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01654250.